There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Unicycive Therapeutics (UNCY – Research Report), Legend Biotech (LEGN – Research Report) and Reviva Pharmaceuticals Holdings (RVPH – Research Report) with bullish sentiments.
Unicycive Therapeutics (UNCY)
In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Unicycive Therapeutics, with a price target of $4.50. The company’s shares closed last Tuesday at $0.76, close to its 52-week low of $0.40.
According to TipRanks.com, Arce is a 5-star analyst with an average return of
Unicycive Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $4.17.
See today’s best-performing stocks on TipRanks >>
Legend Biotech (LEGN)
In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Legend Biotech, with a price target of $85.00. The company’s shares closed last Tuesday at $66.95.
According to TipRanks.com, Kapoor is a 1-star analyst with an average return of
Legend Biotech has an analyst consensus of Strong Buy, with a price target consensus of $89.22, representing a 39.1% upside. In a report released yesterday, Barclays also initiated coverage with a Buy rating on the stock with a $92.00 price target.
Reviva Pharmaceuticals Holdings (RVPH)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Reviva Pharmaceuticals Holdings, with a price target of $10.00. The company’s shares closed last Tuesday at $4.27.
According to TipRanks.com, Selvaraju is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Currently, the analyst consensus on Reviva Pharmaceuticals Holdings is a Strong Buy with an average price target of $15.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on UNCY:
- Unicycive Announces Second Quarter 2023 Financial Results and Provides Business Update
- Unicycive Therapeutics reports Q2 EPS (29c), consensus (34c)
- Unicycive Therapeutics to Participate in the H.C. Wainwright 2nd Annual Kidney Conference
- Unicycive announces publication of results on oxylanthanum carbonate
- Unicycive Therapeutics Announces Publication of Positive Comparison of Oxylanthanum Carbonate to Commercially Available Phosphate Binders in the American Journal of Nephrology
